Celldex Therapeutics, Inc.
Perryville III Building
Suite 220 53 Frontage Road
Hampton, NJ 08827
United States
908 200 7500
https://www.celldex.com
版塊: Healthcare
行業: Biotechnology
全職員工: 160
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Anthony S. Marucci M.B.A. | Founder, President, CEO & Director | 1.27M | 無 | 1962 |
| Dr. Tibor Keler Ph.D. | Founder, Chief Scientific Officer & Executive VP | 810.39k | 無 | 1959 |
| Mr. Sam Martin | Senior VP, CFO, Secretary & Treasurer | 676.87k | 無 | 1971 |
| Dr. Margo Heath-Chiozzi M.D. | Senior Vice President of Regulatory Affairs | 667.21k | 無 | 1957 |
| Dr. Diane C. Young M.D. | Senior VP & Chief Medical Officer | 696.45k | 無 | 1957 |
| Prof. Joseph P. Schlessinger Ph.D. | Co-Founder & Member of Scientific Advisory Board | 無 | 無 | 1945 |
| Ms. Sarah Cavanaugh | Senior Vice President of Corporate Affairs & Administration | 無 | 無 | 1975 |
| Mr. Freddy A. Jimenez Esq. | Senior VP & General Counsel | 579.7k | 無 | 1969 |
| Dr. Ronald A. Pepin | Chief Business Officer & Senior VP | 441.84k | 無 | 1956 |
| Ms. Elizabeth Crowley | Chief Product Development Officer & Senior VP | 507.24k | 無 | 1972 |
描述
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
公司管治
截至 2024年4月29日 止，Celldex Therapeutics, Inc. 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中：2；董事會：2；股東權利：1；現金賠償：5。
